A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection

Benjamin Mordmüller1,2,3,4,5, Zita Sulyok1,2, Mihály Sulyok1,2, Zsófia Molnar1,2, Albert Lahremruata1,2, Carlos Lamsfus Calle1,2, Patricia Granados Bayon1,2, Meral Eser1,2, Markus Gmeiner1,2,4, Jana Held1,2, Henri-Lynn Heimann1,2, Tamirat Gebru Woldearegai1,2, Javier Ibáñez1,2, Judith Flügge1,2, Rolf Fendel1,2, Andrea Kreidenweiss1, Natasha KC5,6, Tooba Murshedkar5, Sumana Chakravarty5, Peter F. Billingsley5, L. W. Preston Church5, Thomas L. Richie5, B. Kim Lee Sim5,6, Stephen L. Hoffman5,7 and Peter G. Kremsner1,2,3,7

Immunization with radiation-attenuated Plasmodium falciparum (Pf) sporozoites (SPZ) in PfSPZ Vaccine, has provided better vaccine efficacy (VE) against controlled human malaria infection (CHMI) with the same parasites as in the vaccine (homologous) than with genetically distant parasites (heterologous). We sought to identify an immunization regimen that provided similar VE against CHMI with homologous and heterologous Pf for at least 9 weeks in malaria-naïve adults. Such a regimen was identified in part 1 (optimization), an open label study, and confirmed in part 2 (verification), a randomized, double-blind, placebo-controlled study in which VE was assessed by cross-over repeat CHMI with homologous (PfNP54) and heterologous (PfPG8) PfSPZ at 3 and 9–10 weeks. VE was calculated using Bayesian generalized linear regression. In part 1, vaccination with 9 × 10⁵ PfSPZ on days 1, 8, and 29 protected 5/5 (100%) subjects against homologous CHMI at 3 weeks after the last immunization. In part 2, the same 3-dose regimen protected 5/6 subjects (83%) against heterologous CHMI at both 3 and 9–10 weeks after the last immunization. Overall VE was 78% (95% predictive interval: 57–92%), and against heterologous and homologous was 79% (95% Pl: 54–95%) and 77% (95% Pl: 50–95%) respectively. PfSPZ Vaccine was safe and well tolerated. A 4-week, 3-dose regimen of PfSPZ Vaccine provided similar VE for 9–10 weeks against homologous and heterologous CHMI. The trial is registered with ClinicalTrials.gov, NCT02704533.

npj Vaccines (2022) 7:100; https://doi.org/10.1038/s41541-022-00510-z

INTRODUCTION

The large international investment in malaria control beginning about 2000, resulted in reduction in numbers of clinical cases and deaths caused by malaria by 19 and 50%, respectively by 2014.1 However, from 2015 to 2019, the numbers of annual cases (229 million in 2019) and deaths (409,000 in 2019) were not reduced1. Our current tools are not sufficient to halt transmission and eliminate malaria in the most affected parts of the world; the World Health Organization reported that in 2020 there were more deaths from malaria than from COVID-19 in sub-Saharan Africa.2

Malaria is also a significant travel-related disease with an average of 1469 hospitalizations and 11 deaths per year in the United States (US) between 2000 and 2014 and greater numbers in Europe (8349 cases in 2018)3,4, most acquired in Africa. Chemoprophylaxis is available, but uptake and compliance are often inadequate leading to cases and deaths caused by malaria3–6.

Vaccines would be powerful antimalarial tools. However, the parasites that cause malaria are much more complex than the viruses and bacteria against which we have vaccines. There is no marketed vaccine in Europe, the US or Africa for a human disease caused by parasites. The most studied malaria vaccine and the closest to marketing is RTS,S/AS017, a subunit recombinant protein vaccine based on the Plasmodium falciparum (Pf) circumsporozoite protein (CSP). The Phase 3 program raised questions about the risk-benefit ratio and to provide further data, RTS,S/AS01 was assessed in a pilot implementation program in 9 month-olds in Africa.6 The pilot program in more than 500,000 infants showed a significant reduction of 30% in severe malaria cases and a significant reduction of 21% in hospitalizations with malaria but no significant reduction in other malaria parameters. The four-dose regimen administered over 21 months is now recommended by WHO beginning at 5 months of age.6 A second vaccine based on the PfCSP, R21 had results comparable to RTS,S/AS01 in a Phase 2 trial, and is now in Phase 310.

PfSPZ Vaccine, comprised of radiation-attenuated, aseptic, purified, cryopreserved Pf sporozoites (SPZ), expresses thousands of proteins and induces protective immunity against the early, clinically silent stages of malaria through antibodies and T cells11–21. It has demonstrated superior vaccine efficacy (VE) as compared to subunit vaccines, inducing greater than 90% VE against controlled human malaria infection (CHMI) in the US and Africa, and significant VE against naturally transmitted malaria in African adults11–18. However, VE against parasites that are genetically and thus antigenically different (heterologous) from the vaccine strain has been lower than VE against homologous parasites. For example, VEs of 92 and 70% were demonstrated against homologous CHMI performed 3 and 24 weeks after vaccination, respectively, using the same West African parasite as
in the vaccine (PfNF54), but only 80 and 10%, respectively, against heterologous CHMI conducted in parallel using the divergent PF7G8 parasite from Brazil. PF7G8 has now been shown to be more distant from PNF54, the vaccine strain, than 704 P. falciparum isolates from West, East, and Central Africa. Furthermore, when the same regimen of PfSPZ Vaccine was assessed against CHMI 6 months after the last dose of PfSPZ Vaccine in the US and against intense transmission of heterogeneous Pf in the field in Mali during the 6 months after the last dose of vaccine, VE was as good, if not better, in the field than against CHMI18,19,21,22. Thus, heterologous CHMI with PF7G8 provides a rigorous assessment of the VE of PfSPZ Vaccine. Strain-transcending protection is required if the vaccine is to protect against the diverse parasites encountered in the field, and we surmised that more effective cross-strain protection could be achieved through an improved vaccination regimen.

This study was designed to identify a PfSPZ Vaccine regimen that could move to late Phase 2 and pivotal Phase 3 clinical trials. The goal was a well tolerated, safe vaccination regimen that could be administered within 28 days and had at least 75% VE for at least 9 weeks (a time period longer than >80% of all travel to Africa) against CHMI with heterologous Pf parasites that are more distant from the vaccine strain than essentially all Pf parasites in Africa, a criterion met by PF7G8. Because PfSPZ of PfSPZ Vaccine develop only partially in the liver and do not replicate, there is less in vivo amplification of the immunogen than with other live vaccines; for this reason, we selected two doses one week apart as the prime (multidose priming). Moreover, since the vaccine induces antibody responses targeting the sporozoite, we were concerned this could diminish the effectiveness of a delayed boost, and therefore selected a short, three-week prime-boost gap to dodge the peak antibody response. We hoped these two features of the immunization regimen would increase vaccine potency and improve cross-strain protection. Finally, we felt that the practicality of a four-week regimen would support timely travel preparations, seasonal malaria prophylaxis in children, protection of newly pregnant women and efficient administration to entire populations in mass vaccination programs.

**RESULTS**

**Trial participants**

From 22 September 2016 to 1 March 2018, 45 volunteers were enrolled sequentially. Nine of the 45 were allocated to a study of the safety and infectivity of Sanaria® PfSPZ Challenge (7G8) that will be reported separately. The remaining 36 were randomized into two cohorts. In part 1 (optimization phase) an optimal regimen was identified. In part 2 (verification phase) the optimal regimen was assessed prospectively to verify its efficacy. During optimization all volunteers received at least one dose of PfSPZ Vaccine and 17/18 completed their schedule and underwent CHMI (Fig. 1b). One volunteer withdrew from further vaccinations and CHMI after the first dose of vaccine for personal reasons and subsequently was followed to monitor safety. All 12 vaccinees and 6 controls in the verification phase completed all inoculations: three vaccinations and two CHMIs. Vaccinations were done with PfSPZ Vaccine or normal saline (placebo), CHMI with PfSPZ Challenge (NF54) and PfSPZ Challenge (7G8). CHMIs were done using a cross-over design with randomly allocated sequences of NF54-7G8 and 7G8-NF54 (Figs. 1b and 2a). One volunteer allocated to PfSPZ Vaccine received the second vaccination on day 15 instead of day 8 (Fig. 1b). The third vaccination was administered and CHMIs were conducted according to schedule. Demographic characteristics were similar between the groups of healthy, malaria-naïve, young adults (Table 1).

**Safety and tolerability**

Immunization with PfSPZ Vaccine was generally well tolerated and safe (Table 2, Supplementary Tables 1–4).

**Optimization Phase.** The results of safety assessment during the optimization phase that did not include controls are described in Supplementary Tables 1–3. At the highest dose of PfSPZ Vaccine (2.7 × 10^6 PfSPZ), one volunteer reported a constellation of grade 3 symptoms the night following the second vaccination (vomiting, chills, hyperhidrosis, myalgia, fatigue) considered related to the vaccination, that subsided over the next 2 days and did not reoccur after CHMI. This volunteer was protected at CHMI. A second participant experienced fever to 39.2°C two days after the 3rd dose of 9.0 × 10^6 PfSPZ accompanied by mild fatigue that resolved by the next day. Two subjects had Grade 3 lymphopenia and one subject had Grade 3 decreased glucose.

**Verification phase.** There was no significant difference between vaccinees and controls in solicited or unsolicited adverse events (AEs) during the immunization period (Table 2). During the immunization period, there were no Grade 3 solicited AEs, no Grade 3 immunization-related unsolicited AEs (Table 2), and no Grade 3 laboratory abnormalities (Supplementary Table 3). One vaccinee did have Grade 3 elevations of systolic blood pressure that was considered to be unrelated to immunization. There was one serious adverse event (SAE) in a placebo recipient who had a sports accident 126 days following the first vaccination. This SAE was not considered related to the study interventions. Lymphopenia was
more commonly observed in the vaccine group (10 of 12 subjects, Supplementary Table 3) than in the placebo controls (0/6, \( p = 0.0015 \), Fisher’s Exact test). Most episodes occurred 1 day after immunization and resolved by the next measurement 6 days later.

**CHMI.** One participant in the optimization phase experienced grade 3 headache and fatigue with CHMI, corresponding to the time of Pf parasitemia. During the verification phase PfSPZ Challenge (NF54) and PfSPZ Challenge (7G8) were safe and caused only mild or moderate symptoms as a result (Supplementary Table 4). The patterns of symptoms were similar for NF54 and 7G8 (Supplementary Table 4). The incidence of headache, the most frequently encountered moderate to severe AE, was higher, but not significantly, in infected and uninfected participants in both phases (5/21 with parasitemia vs. 3/32 without parasitemia, \( p = 0.24 \), Fisher’s exact test) (Supplementary Table 4). Grade 3
lymphopenia, associated with parasitemia, occurred after 2/6 Pf7G8 and 1/6 PfNF54 CHMs.

Vaccine efficacy

**Optimization phase.** All subjects excluding the one drop-out from the first group underwent homologous CHMI with PfSPZ Challenge (NF54) 3 weeks after the last dose of vaccine. The first regimen, $9.0 \times 10^5$ PfSPZ on days 1, 8 and 29 (Group A), met pre-specified VE criteria: none of the 5 subjects undergoing CHMI developed parasitaemia (1-risk ratio x 100% = 100%). The decision tree then directed study flow to a two-dose group receiving $1.35 \times 10^6$ PfSPZ on days 1 and 8 (Group B1), which is the same total dose of PfSPZ as the first regimen ($2.7 \times 10^6$ PfSPZ). This tested the hypothesis that only total dose mattered and that two injections would be as efficacious as three. All six subjects underwent homologous CHMI three weeks later and 2/6 developed parasitemia (1-risk ratio x 100% = 67%), a VE not sufficient to progress to a single dose regimen. The decision tree directed the third group to retain a 2-dose regimen but with an increased dose per injection, in an effort to preserve the simpler 2-dose approach. However, doubling the dose from $1.35 \times 10^6$ to $2.7 \times 10^6$ PfSPZ (Group C2) did not improve VE as 3/6 developed parasitaemia (1-risk ratio x 100% = 50%) (Supplementary Fig. 2).

In summary, only the initial, 3-dose regimen ($9.0 \times 10^5$ PfSPZ on days 1, 8 and 29) met VE criteria. This regimen was therefore selected for transition to the verification phase as the shortest sufficiently efficacious regimen.

**Verification phase.** Twelve participants were administered PfSPZ Vaccine and 6 normal saline placebo according to the 3-dose regimen, and all underwent CHMI 21 days (3 weeks) later; within each arm, half the participants were randomly and blindly assigned to Pf7G8 and half to PfNF54. Forty-two to 47 days later, at 63–68 days after the last dose of vaccine (9–10 weeks), all subjects underwent a second CHMI with the Pf strain reversed (double cross-over design).

CHMI with PfSPZ Challenge (7G8). Among vaccinees who underwent CHMI with PfSPZ Challenge (7G8), 2/12 developed parasitemia (1/6 after the 3 week CHMI and 1/6 after the 9–10 week CHMI) and 6/6 normal saline placebo control subjects developed parasitemia (3/3 after the 3 week CHMI and 3/3 after the
9–10 week CHMI) (Fig. 2). The controls developed parasitemia on day 9 after the first CHMI (3 of 3) or on day 9 (2 of 3) or day 11 (1 of 3) after the second CHMI. One vaccinee developed parasitemia on day 10 after CHMI 1 and one vaccinee developed parasitemia on day 10 after CHMI 2. Crude VE (1-risk ratio) against heterologous CHMI was 83% after each CHMI.

**CHMI with PfSPZ Challenge (NF54).** Among vaccinees who underwent CHMI with PfSPZ Challenge (NF54), 3/12 developed parasitemia (2/6 after the 3 week CHMI and 1/6 after the 9–10 week CHMI) and 5/6 normal saline placebo control subjects developed parasitemia (3/3 after the 3 week CHMI and 2/3 after the 9–10 week CHMI) (Fig. 2). Parasitemia developed in the three controls on day 9 after the first CHMI and in the two positive controls on day 13 after the second CHMI. The three vaccinees who were not protected developed parasitemia on days 11 and 16 (CHMI 1), and 10 (CHMI 2). Crude VE (1-risk ratio) against homologous CHMI was 67% after the first CHMI and 75% after the second CHMI.

Our primary calculation of VE was by proportional analysis using generalized linear regression with a logit link function (logistic regression). Overall VE compared to placebo was 78% (95% predictive interval: 57%; 92%). VEs against PfSPZ Challenge (NF54) and PfSPZ Challenge (7G8) were 77% (95%PI: 50%; 95%) and 79% (95%PI: 54%; 95%), respectively. The prediction interval estimates the uncertainty about future vaccinee response and is therefore larger than a confidence or credible interval. Sensitivity analyses with different priors and frequentist methods were performed and they had no substantial effect on VE estimates.

One volunteer was not protected in either CHMI, three developed parasitaemia once (two in the first and one in the second CHMI) and eight were protected in both CHMIs (Fig. 2a), including the volunteer who received the second vaccination on day 15 (see above).

Repeat CHMI of placebo controls with first PfSPZ (NF54) and second PfSPZ (7G8), or vice versa, resulted in infection rates of 6/6 in the first CHMI and 5/6 in the second CHMI. One placebo recipient developed parasitaemia following first CHMI with Pf7G8 but not following second CHMI with PfNF54. For Pf7G8 the pre-patent periods were 9,9,9 days in the first CHMI and 9,9,11 days in the second CHMI. For PfNF54 they were 9,9,9 days in the first CHMI and 13,13,13 and negative in the second CHMI (Fig. 2). An initial infection with PfNF54 did not impact a subsequent infection with Pf7G8, but an initial infection with Pf7G8 was associated with a delay in the onset of infection with PfNF54 in the second CHMI.

**Immunogenicity**

In the optimization phase, all volunteers developed antibodies to PICSP by the day before CHMI at 3 weeks (Supplementary Fig. 1 and Supplementary Table 6). PfSPZ Vaccine at a dose of 1.35 × 10^8 on day 1 and 8 induced lower antibody concentrations compared to the other regimens (Supplementary Fig. 1 and Supplementary Table 6).

In the verification phase, one day prior to CHMI 1, as compared to pre-immunization, sera from all vaccinees had an increased level of IgG and IgM antibodies to PICSP by enzyme-linked immunosorbent assay (ELISA) and increased inhibition of sporozoite invasion of hepatocytes by inhibition of sporozoite invasion assay (aISI) (Fig. 3a, b, d and Supplementary Tables 7 and 8). However, only 9/12 vaccinees developed IgG antibodies to PfSPZ detected by semi-automated PfSPZ immunofluorescence assay (aIFA) (Fig. 3c and Supplementary Tables 7 and 8). All three of the vaccinees who did not seroconvert in the aIFA were protected from the first CHMI (Fig. 3c). None of the normal saline placebo recipients met the criteria for an increase in activity in any of the three assays. One day prior to CHMI 2, two of the three subjects who had not met the criteria for seroconversion in the aIFA at the time of the first CHMI met criteria for seroconversion. The one non-converter was protected in CHMI 2. (Fig. 3g). Several of the placebo controls met criteria for sero-conversion for IgM antibodies to PICSP (2/6) and PfSPZ by aIFA (3/6), albeit at levels of antibodies much lower than in the vaccinees (Fig. 3f, g); none developed significant activity in aISI assay. There was no significant difference between protected and unprotected vaccinees for any of the assays at CHMI 1 or 2. However, since there were so few unprotected vaccinees, there was little power to show such differences.

**DISCUSSION**

The radiation-attenuated PfSPZ Vaccine is moving forward in clinical development based on reproducible VE against CHMI^13,14,17,25^ and in the field^16,18^. On excellent tolerability and safety^16,18,20,21,26,27^.

More than 6000 doses of PfSPZ of PfSPZ Vaccine containing 5.2 billion PfSPZ have been administered to > 2000 subjects aged 5 months to 61 years in 20 clinical trials in Africa, Europe, and the US without documenting a breakthrough infection. In double blind placebo-controlled trials, including 12 conducted in Africa, there have been no significant differences in adverse events or laboratory abnormalities between vaccinees and normal saline controls^16,18,20,26,28–29^.

The near absence of reactogenicity of PfSPZ Vaccine was confirmed in a recent trial completed in Kenyan infants who were administered three doses of 4.5 × 10^8, 9.0 × 10^8, or 1.8 × 10^9 PfSPZ, the latter twice the dose administered to adults in the current study^27,28^.

We report two major contributions to development of PfSPZ Vaccine for prevention of Pf malaria. We have achieved greater than 75% VE for at least 9 weeks against CHMI with Pf7G8, a Pf parasite that is more distant at the genome, proteome, and CD8 T cell immune response from the NF54 strain of Pf in PfSPZ Vaccine than any of 704 Pf isolates of Pf from East, West, and Central Africa^19^.

We have also reported previously that it was more difficult to protect US adults against CHMI with Pf7G8 at 6 months than Malian adults against Pf naturally acquired in Africa over 6 months of surveillance^14,16,18,19,22^, indicating that CHMI in malaria-naïve adults with Pf7G8 was as, if not more, stringent a test of VE than natural exposure of adults in Africa. This finding suggests that PfSPZ Vaccine protection against Pf7G8 CHMI should translate to protection across the African continent as long as sufficiently robust immune responses can be induced.

Second, we have accomplished this with a 3-dose, 4-week immunization regimen. Compared to the 8 to 24 week regimens often used for vaccines including the early field trials of PfSPZ Vaccine^16–18,20,21,26,28^, this compact regimen will facilitate compliance and support the need for rapid immunization prior to travel and in vaccination programs. We tried to reduce the numbers of doses to two and the time to immunize to 7 days, but this did achieve the same level of VE. We doubt that further condensation of the regimen will provide comparable VE.

The key component of the down-selected regimen may be the two sequential doses in the first week – multidose priming. Prior work indicates that this approach enhances the VE of PfSPZ Vaccine compared to single dose priming^22,29^.

Because the PfSPZ in PfSPZ Vaccine do not replicate, administering two or more doses in a short period of time may better mimic the typical live attenuated vaccines used against many pathogens, which generally replicate over the course of several days before containment by nascent immune responses.

In the optimization phase of the study, we started with a contracted regimen of 3 doses of 9.0 × 10^8 PfSPZ. We protected 100% (5/5) of vaccinees against PfNF54 CHMI at 3 weeks after the last dose. Further contraction to a 1-week, 2-dose regimen decreased VE, despite the same or higher total PfSPZ dose (67 and 50% were protected, respectively). The failure of dose escalation (from 1.35 × 10^8 to 2.7 × 10^6 PfSPZ) to increase VE is...
consistent with prior experience in Africa where escalation from $9.0 \times 10^5$ to $1.8 \times 10^6$ PfSPZ led to a reduction of VE rather than improvement\textsuperscript{17}. As we have described, this may be due to high dose tolerance/suppression of T cell responses\textsuperscript{17}.

In the verification phase of the study we further tested the 3-dose regimen of $9.0 \times 10^5$ PfSPZ on days 1, 8, and 29. At 3 weeks after last immunizing dose half the subjects underwent CHMI with PfSPZ Challenge (NF54) and half with PfSPZ Challenge (7G8). At 9–10 weeks, the subjects who had received CHMI with PfSPZ Challenge (NF54) underwent CHMI with PfSPZ Challenge (7G8) and vice versa. Among those who underwent CHMI with Pf7G8, 6/6 controls developed parasitaemia, and 5/6 (83%) vaccinees were protected at first CHMI and 5/6 (83%) vaccinees were protected at second CHMI. In a prior study, when $9.0 \times 10^5$ PfSPZ was administered 3 times at 8-week intervals, there was 20% VE against Pf7G8 CHMI at 12 weeks\textsuperscript{22}. These data indicate that the
contracted regimen is certainly as good as the longer regimen, and likely superior.

As in previous studies, PfSPZ Vaccine was safe and well tolerated when given at doses up to 2.7 × 10⁶ PfSPZ, although one volunteer reported a transient, self-limiting systemic reaction the evening after receiving the second dose of 2.7 × 10⁶ PfSPZ. Reactogenicity may have resulted from the short time between first and second doses – a seven-day interval vs. the eight-week interval used between doses in the other studies of this dose. Self-limiting systemic reactions were reported in one individual in another trial. An interesting observation was the occurrence of limiting systemic reactions were reported in one individual in another trial. An interesting observation was the occurrence of short, asymptomatic episodes of lymphopenia on the day following vaccination. We selected this timepoint for safety assessments primarily to check for possible signs of liver injury due to the high number of PfSPZ. No evidence of liver injury was detected. Only few vaccine studies report laboratory results shortly following vaccination. Interestingly, in one systematic study on yellow fever vaccine transient drops in lymphocyte counts were also observed.

Vaccination with PfSPZ Vaccine induced antibodies against PfSPZ and the main surface antigen of PfSPZ, PfCSP. These antibodies prevented sporozoite invasion of hepatocytes in vitro. However, in contrast to what we have seen in some previous studies of PfSPZ in malaria naïve adults, and in field studies in Africa, there was no significant association between levels of response in any of the three antibody assays we used, and protection from Pf infection. This may be due to the minimal power to detect significant differences in this small study with only a few unprotected vaccinees, since IgG antibodies to PfCSP and inhibitory activity in the aISI assay were higher in protected vs unprotected vaccinees (Fig. 3). The results of this study were consistent with the results of other studies of PfSPZ Vaccine in that IgM antibodies to PfCSP were apparently higher than IgG antibodies to PfCSP, and were still quite high 9 weeks after the last dose of vaccine. It seems that the class switching from IgM to IgG classically described for responses to viral and bacterial infections, and vaccines against these infections, does not apply to the whole parasites that comprise PfSPZ. The lack of association of antibody results with protection was consistent with the generally accepted concept that the protection by PfSPZ Vaccine is mediated by tissue-resident T cells in the liver, especially CD8+ T cells, that eliminate Pf-infected hepatocytes directly through cytolysis or indirectly by secretion of interferon gamma, which induces infected hepatocytes to produce nitric oxide that eliminates the infected hepatocytes or through a cytokine cascade that leads to the same result. PfSPZ Vaccine in our vaccine express ~1,000 proteins and unfortunately, which and how many of those are involved in the protective efficacy of PfSPZ Vaccine are not known.

In summary, the identified regimen was safe and well-tolerated and protected >75% of vaccinees for at least 9 weeks against CHMI with a heterologous Pf parasite. Based on the results of the present trial, PfSPZ Vaccine was assessed in a Phase 2 trial of women of child-bearing potential in Mali (NCT03989102) and has shown unprecedented protective efficacy against Pf infection and clinical malaria during two malaria transmission seasons over 18 months, is being assessed in a Phase 2 trial in non-immunes (NCT04966871) and in a Phase 2 trial in 6-10-year-old children in Mali (NCT04940130).

METHODS

Trial participants

We recruited healthy, malaria-naïve volunteers, aged 18–45 years at the clinical trial facility of the Institute of Tropical Medicine, Tübingen University Hospital, Germany. Following written informed consent, volunteers underwent medical and laboratory examinations to minimize risks of study participation. Details are given in the accompanying study protocol (Supplement).

Trial design, randomization and treatments

The trial had 2 parts, the first an open-label regimen optimization phase and the second a randomized, double-blind, normal saline placebo controlled verification phase. The aim of the optimization phase was to identify the shortest, well tolerated and efficacious immunization regimen by algorithmically varying the number and size of PfSPZ doses, measuring VE for each regimen using homologous CHMI 3 weeks after vaccination. An adaptive design was used, starting with three doses and navigating through a pre-determined decision tree adjusting dose size and aiming for two- and potentially one-dose regimens depending on whether VE criteria were met (Fig. 1a). The aim of the verification phase was to assess VE of the optimal regimen down-selected from part 1 against both homologous and heterologous CHMI performed 3 and 9–10 weeks after immunization. The blinding and inclusion of normal saline controls in the verification phase also allowed the collection of robust data on tolerability and safety.

Optimization. The immunization regimen was optimized using the pre-specified decision tree with groups of 6 volunteers, starting with 9 × 10⁶ PfSPZ of PfSPZ Vaccine on day 1, 8 and 29. PfSPZ Vaccine was administered by direct venous inoculation (DVI). The maximum single PfSPZ dose was set at 2.7 × 10⁶ PfSPZ. Decisions on either regimen contraction or dose escalation were based on achieving at least 5/6 protected volunteers (Fig. 1a).

Verification. To verify the optimized regimen, volunteers were allocated randomly and blindly to either the optimized PfSPZ Vaccine regimen (n = 12) or to placebo (n = 6). Assignment to PfSPZ Challenge (NF54 and 7GB) at 3 weeks was also done by random allocation and the other strain was then to be administered at 9–10 weeks (double cross-over design); all subjects underwent CHMI twice, first with either the homologous or heterologous Pf parasites and second with the Pf parasites they did not receive in the first CHMI. In the event that a one- or two-dose regimen progressed to the verification phase, a second vaccine group (n = 12 vaccinees and n = 6 controls) using a three-dose regimen (day 1, 8, 29) at the same dose-level (maximum regimen) was to be added.

CHMI. Homologous CHMI was performed using the standard 100% infectious dose of 3.2 × 10⁴ PfSPZ of PfSPZ Challenge (NF54) and heterologous CHMI using the same dose of PfSPZ Challenge (7GB) all doses administered by DVI. No infectivity controls were enrolled for the homologous CHMIs performed during Optimization. This was because all 79 malaria-naïve control subjects who had previously undergone CHMI using PfSPZ Challenge (NF54) in 14 different trials at six different institutions in the US, Germany and Gabon had become positive, indicating that the 3.2 × 10⁴ PfSPZ dose is 100% infectious in malaria-naïve subjects. In addition, stability data for PfSPZ Challenge provided by Sanaria, which like other PfSPZ products is stored in liquid nitrogen vapor phase, indicated essentially no loss in viability over years of testing (data not shown). We were therefore confident that all vaccinees undergoing CHMI in part 1 would receive infectious doses of PfSPZ, and that estimates of VE would be accurate. However, infectivity controls were included in the verification phase. This is because Verification included repeat CHMI, meaning that research subjects were no longer malaria-naïve at the time of the second CHMI. Because 3.2 × 10⁴ PfSPZ of PfSPZ Challenge (NF54) is not always 100% infectious in malaria-exposed individuals, the six placebo recipients were used as infectivity controls for both the first and second CHMI specifically to measure the infectivity of the second CHMI.

Tolerability and safety. During immunization, volunteers were monitored on-site and regularly contacted by telephone. At all visits and calls AEs were collected and coded using the Medical Dictionary for Regulatory Activities (MedDRA Version 22). AEs were collected from the day of first immunization until the day of CHMI at 3 weeks to address the primary safety outcomes - the frequency of related grade 3 (severe) and serious AEs. Samples for hematological and biochemical investigations were taken before, one and before and after each vaccination and during CHMI. Samples for immunological evaluations were taken before the first and 14 days after the third vaccination as well as before, seven and 14 days after each CHMI and on the day of treatment in case parasitemia developed. Additional safety and serum samples were taken 28, 56 and 105 days after the last CHMI.
Malaria diagnosis and treatment. Volunteers were assessed at least daily from day 6 following initiation of CHMI and antimalarial treatment was started when reverse transcription quantitative polymerase chain reaction (RT-qPCR) was positive in at least three measurements, each $>12$ h apart and one of which had to be $>100$ parasites/mL, or if any thick blood smear became positive. The prepatent period was defined as the time from CHMI to the first RT-qPCR with $>100$ parasites/mL. Follow-up visits beyond day 28 post-CHMI were done monthly for 4–6 months. All malaria cases during CHMI were treated with atovaquone-proguanil or artemether-lumefantrine.

Randomization and masking
During Verification the allocation to intervention was nested within the allocation to immunization. The computer-generated randomizations were done by an independent party on the eve of the first immunization day and the first CHMI, respectively. Volunteers and the clinical, immunology, and diagnostic teams were blinded. Unblinded members of the syringe preparation team had no other role in the trial. Allocation was concealed until after the second CHMI. Syringes of PfSPZ Vaccine and placebo were of the same type. PfSPZ Vaccine and placebo have exactly the same appearance.

Statistical analysis
Tolerability and safety data were described and tabulated without formal hypothesis testing. VE, assessed by repeat CHMI, was modelled using Bayesian generalized linear regression and reported with the respective prediction intervals. The model included an intercept and intervention. To calculate strain-specific VE, strain was included as an additional variable. The priors were weakly informative, based on results of previous studies and the optimization phase (intervention).

Parasitological and immunological investigations
Quantitative thick blood smear and ultrasensitive RT-qPCR were done as described previously with lower limits of detection of 5 parasites/µL and the nucleic-acid-equivalent of 6 parasites/mL, respectively. Immunogenicity was assessed by Pf circumsporozoite protein (CSP) by ELISA, and to PfSPZ by automated immunofluorescence assay (aIFA) and automated inhibition of sporozoite invasion assay (aSI) before first vaccination, 14 days following the last dose of vaccine and the day before CHMI as described.

Trial oversight
The trial was approved and overseen by the Paul Ehrlich Institute, the U.S. Food and Drug Administration under an Investigational New Drug application and the Ethics Committee of the Medical Faculty and the University Clinics of the University of Tübingen (Number 023/2016AMG1). An independent monitoring committee oversaw safety aspects of the trial and approved transition from Optimization to Verification. The trial is registered with ClinicalTrials.gov, NCT02704533.

Role of the funding source
The clinical trial was funded by the Deutsches Zentrum für Infekionsforschung (DZIF). Manufacture of PfSPZ Vaccine, PfSPZ Challenge (7GB) and PfSPZ Challenge (7GB) was funded in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health through SBIR award numbers SRA9A0S5837S and SRA9A0S55229. Both funders had no role in planning, conduct, analysis and publication of the results.

Reporting Summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

DATA AVAILABILITY
The data supporting the findings of this study are available within the Article and its Supplementary Information and from the corresponding author upon reasonable request.

Received: 19 October 2021; Accepted: 24 June 2022; Published online: 23 August 2022

REFERENCES
1. World Health Organization. World Malaria Report 2019. 232 (World Health Organization, 2019).
2. World Health Organization. WHO calls for reinvigorated action to fight malaria (News release). Retrieved from https://www.who.int/news/item/30-11-2020-who-calls-for-reinvigorated-action-to-fight-malaria (30 November 2020).
3. Khuu, D. et al. Malaria-Related Hospitalizations in the United States, 2000–2014. Am. J. Trop. Med. Hyg. 97, 213–221 (2017).
4. European Centre for Disease Prevention and Control. Malaria. In ECDC. Annual epidemiological report for 2018. Retrieved from https://www.ecdc.europa.eu/en/publications-data/malaria-annual-epidemiological-report-2018 (Stockholm, 2020).
5. Tatem, A. J. et al. The geography of imported malaria to non-endemic countries: a meta-analysis of nationally reported statistics. Lancet Infect. Dis. 17, 98–107 (2017).
6. Ahtuvallia, J. J., Brooks, S. K., Weinman, J. & Rubin, G. J. A systematic review of factors affecting adherence to malaria chemoprophylaxis amongst travellers from non-endemic countries. Malar. J. 19, 16 (2020).
7. RTS, S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31–45 (2015).
8. World Health Organization. First malaria vaccine in Africa: A potential new tool for child health and improved malaria control. 1–4 (2018).
9. World Health Organization. WHO recommends groundbreaking malaria vaccine for children at risk (News release). Retrieved from https://www.who.int/news/item/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk (6 October 2021).
10. Datoo, M. S., et al. Effectiveness and safety of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. https://doi.org/10.1016/S0140-6736(21)00943-0 (2021).
11. Hoffman, S. L. et al. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccines 6, 9–106 (2010).
12. Epstein, J. E. et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334, 475–480 (2011).
13. Seder, R. A. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359–1365 (2013).
14. Epstein, J. E. et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI insight 2, e89154 (2017).
15. Lyke, K. E. et al. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc. Natl Acad. Sci. USA. 114, 2711–2716 (2017).
16. Sissoko, M. S. et al. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect. Dis. 17, 498–509 (2017).
17. Jongo, S. A. et al. Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults. Clin. Infect. Dis. 71, 2849–2857 (2020).
18. Sissoko, M. S. et al. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infect. Dis. 22, 377–389 (2022).
19. Silva, J. C. et al. Plasmodium falciparum 7GB challenge provides conservative prediction of efficacy of PNTF54-based PfSPZ Vaccine in Africa. Nat. Commun. 13, 3390 (2022).
20. Olutu, A. et al. Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine for Malaria in Healthy Equatorial Guinea. Am. J. Trop. Med. Hyg. 98, 308–318 (2018).
21. Jongo, S. A. et al. Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants. Am. J. Trop. Med. Hyg. 100, 1433–1448 (2019).
22. Lyke, K. E. et al. Multidose Priming and Delayed Boosting Improve PfSPZ Vaccine Efficacy against Heterologous P. falciparum Controlled Human Malaria Infection. Clin. Infect. Dis. 73, e2424–e2435 (2021).
23. CIC Research Inc. Survey of international air travelers, U.S. travelers to overseas, January - March 2012. (ed. 1Q12_US_to_Overseas_Banner_1_30Sep13.pdf) (National Travel and Tourism Office, 2013).
24. Mozer, K. A. et al. Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. Genome Med 12, 6 (2020).
25. Ishizuka, A. S. et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat. Med. 22, 614–623 (2016).
26. Murphy, S. C. et al. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults. Am. J. Trop. Med. Hyg. 99, 338–349 (2018).

27. Steinhardt, L. C. et al. Safety, tolerability, and immunogenicity of PfSPZ Vaccine administered by direct venous inoculation to infants and young children: findings from an age de-escalation, dose-escalation double-blind randomized, controlled study in western Kenya. Clin. Infect. Dis. 71, 1063–1071 (2020).

28. Oneko, M. et al. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat. Med. 27, 1636–1645 (2021).

29. Jonge, S. A. et al. Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults. Am. J. Trop. Med. Hyg. 106, 1215–1226 (2022).

30. Blom, K. et al. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector–to memory-type response. J. Immunol. 190, 2150–2158 (2013).

31. Mwakingwe-Oma, A. et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature 595, 289–294 (2021).

32. Stavnezer, J. & Amemiya, C. T. Evolution of isotype switching. J. Immunol. 167, 636–644 (2017).

33. Duarte, J. H. Functional switching. Nat. Immunol. 17, 512–516 (2016).

34. Schoffel, L. et al. Gamma-interferon, CD8 T cells and antibodies required for immunity to malaria sporozoites. Nature 330, 604–606 (1987).

35. Weiss, W. R., Sedegah, M., Beaudoin, R. L., Miller, L. H. & Good, M. F. CD8 T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl Acad. Sci. U. S. A. 85, 573–576 (1988).

36. Hoffman, S. L. et al. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science 244, 1078–1081 (1989).

37. Doolan, D. L. & Hoffman, S. L. The complexity of protective immunity against liver-stage malaria. J. Immunol. 165, 1453–1462 (2000).

38. Hoffman, S. L., Veckeman, J., Richet, T. L. & Duffy, P. E. The march toward malaria vaccines. Vaccine 33(Suppl 4), D13–23 (2015).

39. Diawara, H. “Malaria Vaccination in Pregnancy: PfSPZ Vaccine in Pregnant Women”, Annual Meeting of the American Society of Tropical Medicine & Hygiene, (Virtual presentation) Nov 19 2021.

40. Roestenberg, M. et al. Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved Plasmodium falciparum Sporozoites. Am. J. Trop. Med. Hyg. 88, 5–13 (2013).

41. Gomez-Perez, G. P. et al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates. Malar. J. 14, 306 (2015).

42. Mordmüller, B. et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar. J. 14, 117 (2015).

43. Mordmüller, B. et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542, 445–449 (2016).

44. Laurens, M. B. et al. Dose dependent infectivity of aseptic, purified, cryopreserved Plasmodium falciparum 7GB sporozoites in malaria-naive adults. J. Infect. Dis. 220, 1962–1966 (2019).

45. Sulyok, Z. et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat. Commun. 12, 2518 (2021).

46. Sulyok, M. et al. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect. Dis. 16, 632–644 (2016).

47. Lell, B. et al. Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon. Am. J. Trop. Med. Hyg. 98, 508–515 (2018).

48. Metzger, W. G. et al. Hericenomy for causal malaria prophylaxis: a randomised controlled human infection trial. Trop. Med. Int. Health 25, 380–386 (2020).

49. Murphy, S. C. et al. PfSPZ-CVac efficacy against malaria increases from 0 to 75% when administered in the absence of erythrocyte stage parasites: A randomized, placebo-controlled trial with controlled human malaria infection. PLoS Pathog. 17, e1009594 (2021).

50. Achan, J. et al. Serologic markers of previous malaria exposure and functional antibodies inhibiting parasite growth are associated with parasite kinetics following a Plasmodium falciparum controlled human infection. Clin. Infect. Dis. 70, 2544–2552 (2019).

51. Kapulu, M. C., Njungu, P. & Hamaluba, M. M. Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-Sika): a study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity. Wellcome Open Res 3, 155 (2019).

52. Joanny, F., Lohr, S. J., Englentiner, T., Lell, B. & Mordmüller, B. Limit of blank and limit of detection of Plasmodium falciparum thick blood smear microscopy in a routine setting in Central Africa. Malar. J. 13, 234 (2014).

ACKNOWLEDGEMENTS
We thank the trial participants for their time and commitment and the team of the Institute of Tropical Medicine, in particular, Antje Theurer, Bianca Eder, Raymond Eid, Murnbeth, Regina Steuder, Cigdem Uyanik, José Fernandes, David Weber, Lilith Berner, Thaisa Lucas Sandri, Diane Egger-Adam, Johanna Weinrich, Fiona O’Rourke, Annette Knoblich, Maddalena Di Lelis for their excellent support. We also thank for expert advice by members of the safety monitoring committee (Alan Cross, Kent Heimer, Heizo Lagler) and fruitful discussions with members of the International PfSPZ Consortium. We thank the teams at Sanaria and Protein Potential for manufacture and shipping of investigational products, PfSPZ Vaccine and diluents, regulatory, quality, and clinical site activities, and legal and administrative support. The clinical trial was funded by the Deutsches Zentrum für Infektionsforschung (German Center for Infection Research – DZIF), award number TTU 03.902. Manufacture of PfSPZ Vaccine, PfSPZ Challenge (NF54) and PfSPZ Challenge (7GB) was funded in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under SBIR award numbers 5R44AI055375 and 5R44AI055229.

AUTHOR CONTRIBUTIONS
B.M. designed the trial, analysed the clinical data, contributed to data collection and drafted the manuscript. Z.S., M.S., Z.M., M.E. and H.L.H. collected clinical data. A.L., P.G.B., J.H., T.G.W., J.I., J.F. R.F. and A.K. collected laboratory data. C.L.C. was responsible for investigational product formulation. Sanaria Inc. provided the investigational product (B.K.L.S.), performed and analysed immunological assays data (N.K.C., S.C., P.R., S.L.H.), interacted with regulatory authorities (T.M.), provided clinical oversight (L.W.P.C., T.L.R., S.L.H.) and critically reviewed the manuscript. M.G. and P.G.K. coordinated study activities. P.G.K. supervised the project. B.M. was the principal investigator, S.L.H. the sponsor representative of the clinical trial. All authors contributed to interpretation of the data and writing of the manuscript.

COMPETING INTERESTS
NKC, SC, PR, LWPC, TLR, BKLS, and SLH are salaried, full-time employees of Sanaria, the developer and sponsor of Sanaria PfSPZ Vaccine and PfSPZ Challenge. SLH and BKLS also have financial interests in Sanaria. BKLS and SLH are inventors on patent and patent applications that have been assigned to Sanaria, BM and PKG received funding from DZIF to conduct the trial. All other authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41541-022-00510-z.

Correspondence and requests for materials should be addressed to Benjamin Mordmüller or Stephen L. Hoffman.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the author’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022

Published in partnership with the Sealy Institute for Vaccine Sciences

npj Vaccines (2022) 100